Dianthus Therapeutics, Inc. /DE/ (DNTH) has 8 SEC Form 4 insider filings on record in the last 90 days. Most recent filing: Sept. 18, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 18, 2026 filed Sept. 17, 2026 | CARR EDWARD CHIEF ACCOUNTING OFFICER | $1,670,046 | 60,000 | 0% | Yes | |
|
|
||||||
| Sept. 3, 2026 filed Sept. 1, 2026 | Randhawa Simrat EVP, Head of R&D | $2,047,233 | 69,372 | 0% | Yes | |
|
|
||||||
| Aug. 19, 2026 | Read Simon Director | $275,550 | 8,334 | 0% | Yes | |
|
|
||||||
| Aug. 11, 2026 filed Aug. 10, 2026 | McGeorge Anne Director | $694,782 | 23,250 | — | Yes | |
|
|
||||||
| Aug. 11, 2026 filed Aug. 10, 2026 | Read Simon Director | $253,246 | 8,331 | 0% | Yes | |
|
|
||||||
Showing the 5 most recent of 8 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free